H.C. Wainwright raised the firm’s price target on Praxis Precision (PRAX) to $258 from $232 and keeps a Buy rating on the shares after meeting with management. The firm believes Praxis is “poised for nether breakout” with the relutrigine readout nearing. Management offered details that should ease an investor concerns regarding the interim readout for EMBOLD Cohort 2 which should bring relutrigine to market in 2026, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Promising Growth Potential for Praxis Precision Medicines: Ulixacaltamide’s Breakthrough in Essential Tremor Treatment
- Praxis Precision participates in a conference call with H.C. Wainwright
- Praxis Precision announces inducement grants under Nasdaq lsiting rule
- Praxis Precision Medicines Reports Q3 2025 Financial Results
- Positive Phase 3 Trial Results and Strong Financial Position Drive Buy Rating for Praxis Precision Medicines